Osteoarthritis Market "to Treble by 2024"

Published on: 

September 20, 2016

The osteoarthritis market across the seven major markets of the US, France, Germany, Italy, Spain, the UK, and Japan is forecast to more than treble from $3.25 billion in 2014 to $10.49 billion by 2024, according to research and consulting firm GlobalData.

The company’s report states that the growth can be attributed to the launch of new biologic therapies priced at a substantial premium to small-molecule therapies, the launch of drugs with novel mechanisms of action (MOAs) and disease-modifying effects, the growth of the osteoarthritis population, and recent improvements in imaging techniques to facilitate the development of disease-modifying osteoarthritis drugs.